Novo Nordisk, a leader in the pharmaceutical industry, reported that Wegovy pills have proven to be more effective in weight loss compared to the newly launched Foundayo pills from Eli Lilly. This announcement comes at a time when competition among manufacturers of obesity medications is intensifying, marking a new phase in the treatment of obesity.
Studies conducted by Novo revealed that Wegovy achieved an average weight loss of up to 16.6%, while Foundayo only managed a 12.4% weight loss rate. This superiority in results reflects the effectiveness of Wegovy as a preferred option for patients seeking to lose weight.
Event Details
In an indirect comparative study, the results of previous studies on the medications were evaluated, showing that Wegovy outperformed Foundayo, which is set to hit the market next week. Novo confirmed that 84% of patients prefer a medication profile similar to semaglutide, the active ingredient in Wegovy, over Foundayo.
These results come at a time when both Novo and Eli Lilly are trying to shape the narrative around their drugs, as these medications are viewed as the beginning of a new phase in the weight loss drug market. It is expected that weight loss pills will contribute to market expansion, as they are easier to distribute compared to injections.
Background & Context
Historically, obesity medications relied heavily on injections, but with the evolution of research, companies have begun developing effective pills. Wegovy was launched in the United States last January, and prescriptions for it quickly surged, with over 600,000 patients starting to use it. This launch is considered one of the best in the history of new medications.
In contrast, Foundayo pills, which represent the latest addition to the market, allow patients to take them without dietary restrictions, making them more convenient for daily routines. However, Wegovy requires consumption on an empty stomach with a small amount of water, which may affect its acceptance.
Impact & Consequences
Analyses indicate that Wegovy pills may contribute to improving patients' quality of life by reducing the side effects associated with obesity medications. Studies have shown that Foundayo was linked to a 14-fold increase in the likelihood of patients discontinuing treatment due to side effects compared to Wegovy.
The most common side effects of GLP-1 medications include gastrointestinal issues such as nausea, vomiting, and diarrhea, making Wegovy's effectiveness in reducing these effects an additional strength in the market.
Regional Significance
With rising obesity rates in the Arab world, these medications could provide effective solutions for many individuals struggling with weight issues. Obesity is a major health concern in the region, making the availability of effective treatment options critically important.
As interest in weight loss medications grows, the Arab market is expected to see increased attention towards these drugs, potentially contributing to improved public health and reduced risks associated with obesity.